{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:19:58Z","timestamp":1761895198761},"reference-count":171,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:00:00Z","timestamp":1290470400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mount Sinai J Medicine"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The myeloproliferative neoplasms represent a diverse group of hematologic malignancies that have been the subject of intense investigation over the last decade. Although clinical trials of the much anticipated small molecule inhibitors of Janus kinase 2 have shown that these experimental agents are successful in palliating many of the symptoms associated with the myeloproliferative neoplasms, they have not been reported to affect the disease initiating hematopoietic stem cell population or to alter the natural history of these disorders. Investigators remain optimistic that new information about the genetic and cellular origins gained from the efforts of numerous laboratories will ultimately translate in to the identification of new drug targets and more effective therapies. We hypothesize that ultimately, the use of combinations of drugs including chromatin modifying agents, immunomodulatory agents, anti\u2010apoptotic agents, cellular therapies and monoclonal antibodies will be required to effectively treat patients with myeloproliferative neoplasms. <jats:bold><jats:italic>Mt Sinai J Med 77:667\u2013683, 2010.<\/jats:italic><\/jats:bold> \u00a9 <jats:italic>2010 Mount Sinai School of Medicine<\/jats:italic><\/jats:p>","DOI":"10.1002\/msj.20225","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T10:17:10Z","timestamp":1290593830000},"page":"667-683","source":"Crossref","is-referenced-by-count":5,"title":["Myeloproliferative Neoplasms: New Translational Therapies"],"prefix":"10.1002","volume":"77","author":[{"given":"John","family":"Mascarenhas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,23]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_10_3_2","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood","volume":"64","author":"Bennett JH.","year":"1845","journal-title":"Edinb Med Surg J"},{"key":"e_1_2_10_4_2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(87)80035-5"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07436.x"},{"key":"e_1_2_10_9_2","first-page":"384","article-title":"[Sur une forme sp\u00e9ciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante]","volume":"44","author":"Vaquez H.","year":"1892","journal-title":"CR Soc Biol (Paris)"},{"key":"e_1_2_10_10_2","first-page":"143","article-title":"Chronic cyanosis with polycythaemia and enlarged spleen: a new clinical entity","volume":"1","author":"Osler W.","year":"1903","journal-title":"Am J Med Sci"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_2_10_12_2","first-page":"183","article-title":"Polycythemia Vera Study Group: a historical perspective","volume":"23","author":"Wasserman LR.","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_10_13_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_10_14_2","first-page":"17","article-title":"From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman SM","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_10_16_2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.2.106"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401706"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_10_21_2","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"13","author":"Faderl S","year":"1999","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.21.1616"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404500"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121434"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.72"},{"key":"e_1_2_10_27_2","first-page":"172","volume-title":"Hematology 1999","author":"Tefferi A.","year":"1999"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.3.1013.1013"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_10_30_2","unstructured":"MascarenhasJ HoffmanR.Risk adapted approach to the treatment of primary myelofibrosis.Hematology Education: the education program for the annual congress of the European Hematology Association.2009;3:192\u2013199."},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000040008"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_10_34_2","doi-asserted-by":"crossref","unstructured":"MesaR YaoX CripeLD et al.Lenalidomide and prednisone for primary and post polycythemia vera\/essential thrombocythemia myelofibrosis (MF): an Eastern Cooperative Oncology Group (ECOG) phase II trial. Paper presented at: American Society of Hematology Annual Meeting; December 6 2008; San Francisco CA.","DOI":"10.1182\/blood.V112.11.1753.1753"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05524.x"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05229.x"},{"key":"e_1_2_10_37_2","first-page":"616","article-title":"rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: experience in 6 patients and meta\u2010analytical approach","volume":"83","author":"Rodr\u00edguez JN","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb04658.x"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10076"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1984.tb00724.x"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03331.x"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3843198.x"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4299"},{"key":"e_1_2_10_45_2","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study","volume":"93","author":"Guardiola P","year":"1999","journal-title":"Blood"},{"issue":"15","key":"e_1_2_10_46_2","article-title":"First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: interim analysis of MPD\u2010RC 101 protocol","volume":"28","author":"Rondelli D","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3343"},{"key":"e_1_2_10_49_2","doi-asserted-by":"crossref","unstructured":"DeiningerM O'BrienSG GuilhotF et al.International randomized study of interferon vs STI571 (IRIS) 8\u2010year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib. Paper presented at: American Society of Hematology Annual Meeting; December 5\u20138 2009; San Francisco CA. Abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_10_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100268"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"issue":"15","key":"e_1_2_10_61_2","article-title":"Safety and efficacy of bosutinib (SKI\u2010606) in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib","volume":"28","author":"Cortes JE","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_62_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR\u2010ABL\/IGF\u20101R\/Aurora kinase inhibitor XL228 in patients with Ph+ + leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes J","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011239"},{"key":"e_1_2_10_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113175"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112573"},{"issue":"5","key":"e_1_2_10_66_2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"J\u00f8rgensen HG","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.52"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0954"},{"key":"e_1_2_10_69_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2185.2185","article-title":"Peptide\u2010vaccine treatment associated with TKI therapy in patients with CML is able to induce immunologic, cytogenetic and molecular responses: a single center experience with long\u2010term follow up","volume":"114","author":"Abruzzese E","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)70931-4"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0250"},{"key":"e_1_2_10_72_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.1094.1094","article-title":"Preliminary results from a phase 2 trial of AG\u2010858, an autologous heat shock protein\u2010peptide vaccine, in combination with imatinib in patients with chronic phase chronic myeloid leukemia (CML) resistant to prior imatinib monotherapy","volume":"106","author":"Marin D","year":"2005","journal-title":"Blood"},{"key":"e_1_2_10_73_2","first-page":"1810","article-title":"Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group","volume":"91","author":"Gale RP","year":"1998","journal-title":"Blood"},{"issue":"3","key":"e_1_2_10_74_2","first-page":"S1","article-title":"Marrow transplantation for CML: the Seattle experience","volume":"17","author":"Clift RA","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"e_1_2_10_75_2","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz MM","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1971"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601233140403"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-055186"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.218"},{"key":"e_1_2_10_80_2","first-page":"68","article-title":"Hematopoietic stem cell transplantation for T315I\u2010mutated chronic myelogenous leukemia","volume":"15","author":"Basak G","year":"2010","journal-title":"Ann Transplant"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0675"},{"key":"e_1_2_10_82_2","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long\u2010term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2619"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700933"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.12.2462.2462"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.8.2310.2310"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401133300204"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.90"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404534"},{"key":"e_1_2_10_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-008-9025-4"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404810"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101576"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404971"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06348.x"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.47"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.141"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07697.x"},{"key":"e_1_2_10_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.20"},{"key":"e_1_2_10_107_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.065862"},{"key":"e_1_2_10_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.69"},{"key":"e_1_2_10_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002030"},{"key":"e_1_2_10_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4824"},{"key":"e_1_2_10_111_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-009-0037-y"},{"key":"e_1_2_10_112_2","article-title":"Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF\u2010SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial","volume":"114","author":"Mesa RA","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_113_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3905.3905","article-title":"Phase I dose\u2010escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post\u2013essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"114","author":"Verstovsek S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_114_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.39.1059"},{"key":"e_1_2_10_115_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3775"},{"key":"e_1_2_10_116_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083402"},{"key":"e_1_2_10_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246363"},{"key":"e_1_2_10_118_2","doi-asserted-by":"crossref","unstructured":"HexnerE GoldbergJD PrchalJT et al.A multicenter open label phase I\/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD\u2010RC). Paper presented at: American Society of Hematology Annual Meeting; December 7 2009; New Orleans LA.","DOI":"10.1182\/blood.V114.22.754.754"},{"key":"e_1_2_10_119_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.753.753","article-title":"An open\u2010label study of CEP\u2010701 in patients with JAK2 V617F\u2010positive PV and ET: update of 39 enrolled patients","volume":"114","author":"Moliterno AR","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_120_2","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post\u2013polycythemia vera, or post\u2013essential thrombocythemia myelofibrosis","volume":"112","author":"Shah NP","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_121_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072067"},{"key":"e_1_2_10_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"e_1_2_10_123_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"issue":"1","key":"e_1_2_10_124_2","first-page":"21","article-title":"Effects of treatment with 5\u2010azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman LR","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_10_125_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2485"},{"key":"e_1_2_10_126_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3249"},{"key":"e_1_2_10_127_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3238"},{"key":"e_1_2_10_128_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1823"},{"key":"e_1_2_10_129_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.91"},{"key":"e_1_2_10_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.136"},{"key":"e_1_2_10_131_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07541.x"},{"key":"e_1_2_10_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.05.008"},{"key":"e_1_2_10_133_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2809.2809","article-title":"Phase II trial of low dose, subcutaneous decitabine in myelofibrosis","volume":"112","author":"Odenike OM","year":"2008","journal-title":"Blood"},{"key":"e_1_2_10_134_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7000","article-title":"A phase I\/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium","volume":"26","author":"Silverman LR","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_10_135_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-098061"},{"key":"e_1_2_10_136_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1175.1175","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results","volume":"110","author":"Galli M","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404860"},{"key":"e_1_2_10_138_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.555.555","article-title":"Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor","volume":"110","author":"Guerini V","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_139_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.308.308","article-title":"A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post\u2013polycythemia\/essential thrombocythemia myelofibrosis (Post\u2010PV\/ET MF)","volume":"114","author":"Mascarenhas J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"e_1_2_10_141_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)43764-1"},{"key":"e_1_2_10_142_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.4.1014.1014"},{"key":"e_1_2_10_143_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb08324.x"},{"key":"e_1_2_10_144_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02647.x"},{"key":"e_1_2_10_145_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697629"},{"key":"e_1_2_10_146_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.0.CO;2-A"},{"key":"e_1_2_10_147_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2287"},{"key":"e_1_2_10_148_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2093.h8002093_2093_2099"},{"key":"e_1_2_10_149_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_10_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92625-6"},{"key":"e_1_2_10_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92881-4"},{"key":"e_1_2_10_152_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110973"},{"key":"e_1_2_10_153_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403217"},{"key":"e_1_2_10_154_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280"},{"key":"e_1_2_10_155_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_10_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90508-N"},{"key":"e_1_2_10_157_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2597"},{"key":"e_1_2_10_158_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802263380902"},{"key":"e_1_2_10_159_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0263"},{"key":"e_1_2_10_160_2","article-title":"Treatment with pegylated interferon alpha 2a in combination with the Bcl\u2010Xl inhibitor ABT\u2010737 specifically targets JAK2V617F positive hematopoietic progenitor cells from patients with polycythemia vera","volume":"114","author":"Lu M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_161_2","article-title":"Treatment in vitro with a combination of Bcl\u2010Xl inhibitor\u2010ABT\u2010737 and a JAK2 inhibitor selectively eliminates JAK2V617F MPN progenitor cells","volume":"114","author":"Lu M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_162_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.059"},{"key":"e_1_2_10_163_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005043421807"},{"key":"e_1_2_10_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00135-1"},{"key":"e_1_2_10_165_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2022"},{"key":"e_1_2_10_166_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04970.x"},{"key":"e_1_2_10_167_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08734"},{"key":"e_1_2_10_168_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2914.2914","article-title":"The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms","volume":"114","author":"Vannucchi AM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_169_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.307.307","article-title":"RAD001, an inhibitor of mTOR, shows clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (PPV\/PET MF)","volume":"114","author":"Vannucchi AM","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_170_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202741"},{"key":"e_1_2_10_171_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.2651.2651","article-title":"Synergistic activity of co\u2010treatment with PIM1 kinase inhibitor SGI\u20101776 and histone deacetylase inhibitor panobinostat or heat shock protein 90 inhibitor AUY922 against human CML and myeloproliferative neoplasm (MPN) cells","volume":"114","author":"Fiskus WC","year":"2009","journal-title":"Blood"},{"key":"e_1_2_10_172_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222133"}],"container-title":["Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20225","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msj.20225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:25:16Z","timestamp":1700569516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msj.20225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":171,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/msj.20225"],"URL":"https:\/\/doi.org\/10.1002\/msj.20225","archive":["Portico"],"relation":{},"ISSN":["0027-2507","1931-7581"],"issn-type":[{"value":"0027-2507","type":"print"},{"value":"1931-7581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}